Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1989 May;134(5):1063–1068.

Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading.

P Kaudewitz 1, O Braun-Falco 1, M Ernst 1, M Landthaler 1, W Stolz 1, J Gerdes 1
PMCID: PMC1879900  PMID: 2719076

Abstract

The growth fraction (GF) of 72 human malignant melanomas was determined by immunostaining with monoclonal antibody Ki-67. A positive correlation of GF and histopathologically-assessed prognostic variables, such as tumor thickness, mitotic rate, and prognostic index, was found. Individual Ki-67 values were considerably scattered in all histologically defined groups of malignancy. Thus, GF as determined by Ki-67 was used to calculate a modified prognostic index. In contrast to the histologically defined prognostic index, the Ki-67 based prognostic index allows further subdivision of thin malignant melanomas with no or few mitotic figures. This may be of help in identifying tumors with a high recurrence potential.

Full text

PDF
1063

Images in this article

1064Figure 1
on p.1064

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970 Nov;172(5):902–908. doi: 10.1097/00000658-197011000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  3. Everall J. D., Dowd P. M. Diagnosis, prognosis, and treatment of melanoma. Lancet. 1977 Aug 6;2(8032):286–289. doi: 10.1016/s0140-6736(77)90965-5. [DOI] [PubMed] [Google Scholar]
  4. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  5. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  6. Gerdes J., Stein H., Pileri S., Rivano M. T., Gobbi M., Ralfkiaer E., Nielsen K. M., Pallesen G., Bartels H., Palestro G. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet. 1987 Aug 22;2(8556):448–449. doi: 10.1016/s0140-6736(87)90977-9. [DOI] [PubMed] [Google Scholar]
  7. Grogan T. M., Lippman S. M., Spier C. M., Slymen D. J., Rybski J. A., Rangel C. S., Richter L. C., Miller T. P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988 Apr;71(4):1157–1160. [PubMed] [Google Scholar]
  8. Kopf A. W., Gross D. F., Rogers G. S., Rigel D. S., Hellman L. J., Levenstein M., Welkovich B., Friedman R. J., Roses D. F., Bart R. S. Prognostic index for malignant melanoma. Cancer. 1987 Mar 15;59(6):1236–1241. doi: 10.1002/1097-0142(19870315)59:6<1236::aid-cncr2820590634>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Kuehnl-Petzoldt C., Keil H., Schoepf E. Prognostic significance of the patient's sex, tumor site, and mitotic rate in thin (less than or equal to 1.5 mm) melanoma. Arch Dermatol Res. 1984;276(3):151–155. doi: 10.1007/BF00414011. [DOI] [PubMed] [Google Scholar]
  10. Larsen T. E., Little J. H., Orell S. R., Prade M. International pathologists congruence survey on quantitation of malignant melanoma. Pathology. 1980 Apr;12(2):245–253. doi: 10.3109/00313028009060079. [DOI] [PubMed] [Google Scholar]
  11. Maize J. C. Primary cutaneous malignant melanoma. J Am Acad Dermatol. 1983 Jun;8(6):857–863. doi: 10.1016/s0190-9622(83)80017-6. [DOI] [PubMed] [Google Scholar]
  12. Schmoeckel C., Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol. 1978 Jun;114(6):871–873. [PubMed] [Google Scholar]
  13. Shaw H. M., McCarthy W. H., McCarthy S. W., Milton G. W. Thin malignant melanomas and recurrence potential. Arch Surg. 1987 Oct;122(10):1147–1150. doi: 10.1001/archsurg.1987.01400220057011. [DOI] [PubMed] [Google Scholar]
  14. Suffin S. C., Waisman J., Clark W. H., Jr, Morton D. L. Comparison of the classification by microscopic level (stage) of malignant melanoma by three independent groups of pathologists. Cancer. 1977 Dec;40(6):3112–3114. doi: 10.1002/1097-0142(197712)40:6<3112::aid-cncr2820400654>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  15. Tonak J., Hermanek P., Hornstein O. P., Weidner F. Therapie des malignen Melanoms der klinischen Stadien I und II. Ergebnisse bei 195 Patienten. Dtsch Med Wochenschr. 1976 Mar 19;101(12):435–450. doi: 10.1055/s-0028-1104102. [DOI] [PubMed] [Google Scholar]
  16. Van Der Esch E. P., Cascinelli N., Preda F., Morabito A., Bufalino R. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer. 1981 Oct 1;48(7):1668–1673. doi: 10.1002/1097-0142(19811001)48:7<1668::aid-cncr2820480732>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES